OTC · ADTX
Aditxt, Inc.
Healthcare · Biotechnology
$0.000.00% ($0.00)at close
As of 3:21 PM ET
Market cap
$399.19K
P/E
N/M
EPS (TTM)
-$2,575.18
Next earnings
Per-share valuation inputs need verification
Event dated Mar 31, 2026Market-derived shares outstanding and recent statement shares differ materially. Per-share ratios and valuation outputs may be unreliable until the share base is verified. This sometimes appears with ADRs or provider share-count gaps.
Valuation
Revenue & margin DCF
A cash-flow estimate wouldn't be reliable here
Enterprise value of $432.59K does not cover net debt of $1.14M, so equity value is negative and no fair value per share can be shown. The projected cash flows are positive; the shortfall is in the equity bridge, not the forecast. This engine cannot separate captive-finance or other non-operating borrowings from operating debt.
Reported operating earnings and the comparable cash-flow estimate differ substantially; the model retains the reported-margin anchor.
Data notes
Reported operating earnings and the comparable cash-flow estimate differ substantially; the model retains the reported-margin anchor.
- 10-yr revenue CAGR
- 19.6%
- Ending operating margin
- 0.0%
- Discount rate
- 14.2%
USD · TTM ending Mar 31, 2026 · Price used $0.00 · Price Oct 30, 7:21 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
Note: The latest financial period used here ended about 7 months ago, so a newer report is probably out. Metrics shown may not reflect it.
What changed
The stock fell 100% over the last year. Revenue declined 74.09% over the trailing twelve months. Operating margin moved from -39,651.08% to -127,821.37%. Free cash flow grew 17.49% over the trailing twelve months.
What the market seems to be pricing
The market appears to be responding to weaker operating momentum rather than only rerating the stock.
What would invalidate this read
Operating margin stands at -127,821.37%. Revenue declined 74.09% — this read reverses if that trend stabilizes. If margins and cash flow stabilize while the stock stays depressed, the gap shifts from fundamental damage toward pure multiple compression.
Return analysis
Company profile
Aditxt, Inc. is a biotechnology firm dedicated to advancing immune system health through innovative mapping and reprogramming techniques.
Market multiples
Stock splits
Every 27 shares became 1
Every 8 shares became 1
Every 113 shares became 1
Every 250 shares became 1
Every 40 shares became 1
Every 40 shares became 1
Every 50 shares became 1
Profitability & growth
Analyst consensus
1
Buy
1
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Actuals vs estimates by quarter, or any quarter against the same one a year earlier.
Next report
Dec 2, 2026
Q2 FY26 · EPS est -$24,408,000,000.00 · Revenue est $1.0M
Q1 FY26
Reported May 20, 2026 · Latest
HoverTap a quarter to inspect
Actual
-$2.06
Estimate
-$2,245,536,000.00
Year over year
n/m
Vs prior quarter
n/m
4 beats in the last 4 quarters
Institutional Sentiment
Aditxt, Inc. · ADTX
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.